M
Malcolm K. Brenner
Researcher at Center for Cell and Gene Therapy
Publications - 632
Citations - 50064
Malcolm K. Brenner is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 109, co-authored 606 publications receiving 45233 citations. Previous affiliations of Malcolm K. Brenner include St. Jude Children's Research Hospital & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.
LaQuisa Hill,Rayne H. Rouce,Tyler Smith,Blakely Boriskie,Madhuwanti Srinivasan,Sachin G. Thakkar,Huibin Zhang,Birju Mehta,Juntima Sritabal-Ramirez,Bambi Grilley,Helen E. Heslop,Malcolm K. Brenner,Maksim Mamonkin +12 more
TL;DR: In this article , the authors developed a 2nd generation CD5 CAR that produces minimal T cell fratricide without additional engineering, and they evaluated whether blocking tonic signaling with tyrosine kinase inhibitors (TKI) ibrutinib and dasatinib improves anti-leukemic activity of CD5CAR T cells in patients with r/r T-ALL.
Journal ArticleDOI
LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia
Lauren D. Scherer,Candise Tat,Timothy Sauer,Haruko Tashiro,Swati Naik,Mireya Paulina Velasquez,Stephen Gottschalk,Cliona M. Rooney,Malcolm K. Brenner,Bilal Omer +9 more
TL;DR: In this paper , the LigandCD70.CAR was proposed for acute myeloid leukemia (AML) by using a binder derived from human CD27 protein, the only known ligand of CD70.
Book ChapterDOI
Contributors
Poulomi Adhikari,Jun Ando,Miki Ando,Bipasha Bose,Malcolm K. Brenner,Kirstine Calloe,Hee Cheol Cho,Jonathan M. Cordeiro,Chandrima Dey,Camila Vazquez Echegaray,Hiroshi Egusa,Keiichi Fukuda,Yoshiki Furukawa,Yujiang Gao,Ranadeep Gogoi,Alejandra Guberman,Pengcheng Han,Krishna Kumar Haridhasapavalan,Ping He,Michelle Jankova,Richard Jeske,Saketh Kapoor,Shintaro Kinoshita,Akira Kunitomi,Yan Li,Hiromitsu Nakauchi,Irina Neganova,Thanaphum Osathanon,Jun Pu,Khyati Raina,Sébastien Sart,Sudheer P. Shenoy,Pradeep Kumar Sundaravadivelu,Samydurai Sudhagar,Madhuri Thool,Rajkumar P. Thummer,Jacqueline A. Treat,Vishalini Venkatesan,Xinxia Wang,Ruifan Wu,V. Yang,Lei Ye,Xuegang Yuan +42 more
Journal ArticleDOI
Off‐the‐shelf cd30.car‐modified epstein‐barr virus‐specific t cells (cd30.car ebvsts) provide a safe and effective therapy for patients with hodgkin lymphoma (hl)
Carlos A. Ramos,David H. Quach,Premal Lulla,Rayne H. Rouce,Haran R. Ganesh,Nazila Nouraee,Yolanda D. Briones,Luis Becerra-Dominguez,Suruchi Thakkar,Birju Mehta,Silvana Perconti,Emily M. Hsieh,H. Zhang,Bambi Grilley,Natasha Lapteva,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney +17 more
TL;DR: Tessa et al. as mentioned in this paper used EBV-specific T cells (EBVST), which are virus specific rather than allo-specific and have not produced GVHD in over 300 allogeneic recipients.